Patient Chart Audit Reveals Changing Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Dynamics As New Competition Challenges Alexion/Astra Zeneca's Soliris and Ultomiris
21. November 2024 09:27 ET
|
Spherix Global Insights
EXTON, PA, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Spherix Global Insights has released its first annual chart audit study in hematology, Patient Chart Dynamix™ : Paroxysmal Nocturnal Hemoglobinuria (PNH)...
Hope on the Horizon: Nephrologists Emphasize Need for Innovative C3G Treatments as Novartis and Apellis Prepare Therapies for FDA Submission
15. November 2024 13:15 ET
|
Spherix Global Insights
EXTON, PA, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Complement 3 glomerulopathy (C3G) is a rare, progressive kidney disease characterized by inflammation and kidney damage. Patients with C3G often...
Tremfya's Promising Debut Boosts Momentum for IL-23 Class in Ulcerative Colitis Treatment, According to Spherix Global Insights
15. November 2024 09:38 ET
|
Spherix Global Insights
EXTON, PA, Nov. 15, 2024 (GLOBE NEWSWIRE) -- In what has been a transformative year for ulcerative colitis (UC) treatment, the IL-23 class has solidified its role as a key therapeutic treatment...
Spherix Global Insights Focuses on Earlier use of Advanced Treatments in Hidradenitis Suppurativa (HS) as a Catalyst for Better Patient Outcomes
07. November 2024 17:09 ET
|
Spherix Global Insights
EXTON, PA, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Spherix Global Insights has published a new white paper, Earlier Diagnosis and Treatment: The Key to Better Outcomes in Hidradenitis Suppurativa,...
Critical Gaps in FSGS Treatment Highlight Need for New Therapies, with Pipeline Assets from Travere, Vertex, and Dimerix Poised to Address Unmet Needs
01. November 2024 09:17 ET
|
Spherix Global Insights
EXTON, PA, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Focal segmental glomerulosclerosis (FSGS), one of the most common glomerular diseases seen by nephrologists, ranks among the top three rare kidney...
US Rheumatologists and Dermatologists Report Over Half of their Dermatomyositis Patients Not Optimally Managed, According to Spherix Global Insights
18. Oktober 2024 10:56 ET
|
Spherix Global Insights
EXTON, PA, Oct. 18, 2024 (GLOBE NEWSWIRE) -- Dermatomyositis (DM) is a rare inflammatory disease characterized by muscle weakness and a distinctive skin rash. Currently, the standard of care...
Shifts in the Psoriasis Market Suggest Strong Potential for Emerging Oral Therapies
16. Oktober 2024 14:48 ET
|
Spherix Global Insights
EXTON, PA, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Biologics have long been the cornerstone of psoriasis (PsO) treatment, valued for their proven efficacy and safety. However, the growing demand for...
Hemophilia Markets Poised for Evolution as Competitive Dynamics between Hemlibra (Roche/Genentech) and Altuviiio (Sanofi) Intensify and Hympavzi (Pfizer) Receives Approval, According to Spherix Global Insights
14. Oktober 2024 12:33 ET
|
Spherix Global Insights
EXTON, PA, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Hemophilia, a genetic disorder that impairs blood clotting, affects thousands of people worldwide. The treatment landscape is rapidly evolving, fueled by...
Roche/Genentech’s Gazyva Poised to Transform Lupus Nephritis Treatment After Positive Phase III Results
10. Oktober 2024 10:28 ET
|
Spherix Global Insights
EXTON, PA, Oct. 10, 2024 (GLOBE NEWSWIRE) -- While GSK’s Benlysta (belimumab) and Aurinia’s Lupkynis (voclosporin) have been important advances in the treatment arsenal for lupus nephritis (LN), a...
US Rheumatologists Identify BAFF-R Inhibitors as the Most Promising Treatment Approach for Sjögren’s Disease, According to Spherix Global Insights
02. Oktober 2024 12:27 ET
|
Spherix Global Insights
EXTON, PA, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Sjögren’s disease is a systemic autoimmune rheumatic condition that can profoundly affect a patient's overall functioning. Common symptoms include...